CClinicalTrials.gg
Sign In
CompletedNCT00771069CRYSTAL-COUpdated Dec 3, 2010

Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension

An observational study in Hypertension, sponsored by AstraZeneca. Completed at 13 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-03.

Sponsored by AstraZeneca · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

This study will address the treatment rate and control rate of hypertension, treatment pattern and factors to affect blood pressure control by examining (retrospective) medical records of Type II DM patients with DM related complication and hypertension, among outpatients coming to the Endocrinology Department in 20 general hospital settings nationwide.

02

Conditions studied

  • Hypertension

Keywords

  • Hypertension
  • Type II DM
  • DM related complication
  • JNC7
  • 2007 ESH-ESC guidelines
  • survey
03

In context

Hypertension

6,687 studies on the registry are indexed under Hypertension; 964 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 210 across 1,358 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Type II Diabetes Mellitus patients with Complication and Hypertension

Inclusion criteria

  • After diagnosed type II DM, patients received treatment for a least 3 years
  • Type II DM patients with hypertension and its complication.
  • Visited out-patients to care center after 1 Jan. 2008

Exclusion criteria

Exclusion Criteria:

  • Secondary hypertension patients
  • Patients not receiving hypertension medication
  • Patients stopping BP medication, by physician's order
  • Patients currently enrolled in other clinical studies
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)

Groups and cohorts

  • 1

    Type II Diabetes Mellitus patients with Complication and Hypertension

06

What researchers measure

Primary outcomes

  1. Attainment rate to the target blood pressure.

    Time frame: After collecting all Patient Record Form.

Secondary outcomes

  1. Attainment to the target blood pressure will be investigated according to DM related complications.

    Time frame: After collecting all Patient Record Form.

  2. Change in the DBP/SBP value will be investigated according to the DM Complication

    Time frame: After collecting all Patient Record Form.

  3. Treatment pattern and factors that affect BP control

    Time frame: After collecting all Patient Record Form.

07

Study locations

13 sites
  • Research Site
    Bucheon, Gyeonggi, Korea, Republic of
  • Research Site
    Goyang, Gyeonggi, Korea, Republic of
  • Research Site
    Guri, Gyeonggi, Korea, Republic of
  • Research Site
    Sungnam, Gyeonggi, Korea, Republic of
  • Research Site
    Suwon, Gyeonggi, Korea, Republic of
  • Research Site
    Wonju, Kangwon, Korea, Republic of
  • Research Site
    Jeonju, Keollabuk, Korea, Republic of
  • Research Site
    Busan, Korea, Republic of
  • Research Site
    Deagu, Korea, Republic of
  • Research Site
    Deajeon, Korea, Republic of
  • Research Site
    Incheon, Korea, Republic of
  • Research Site
    Kwangju, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00771069
Lead sponsor
AstraZeneca
First posted
Oct 10, 2008
Start date
Nov 2008
Primary completion
Mar 2009
Completion
Mar 2009
Last update
Dec 3, 2010

Study contacts

Joonwoo Bahn
study director · Astrazenca Korea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypertension→

Other studies from this sponsor

AstraZeneca

Start the discussion